Open Access

Efficacy of paracetamol for the treatment of patent ductus arteriosus in preterm neonates

  • Gianluca Terrin1Email author,
  • Francesca Conte2,
  • Antonella Scipione2,
  • Erica Bacchio2,
  • Maria Giulia Conti2,
  • Rosalia Ferro2,
  • Flavia Ventriglia2 and
  • Mario De Curtis2
Italian Journal of Pediatrics201440:21

DOI: 10.1186/1824-7288-40-21

Received: 6 December 2013

Accepted: 16 February 2014

Published: 20 February 2014

Abstract

Inhibitors of the cyclo-oxygenase component of prostaglandin-H2 synthetase, namely indomethacin and ibuprofen, are commonly used in the treatment of hemodynamically significant patent ductus arteriosus. These drugs are associated with serious adverse events, including gastrointestinal perforation, renal failure and bleeding. The role of paracetamol, an inhibitor of the peroxidase component of prostaglandin-H2 synthetase, has been proposed for the treatment of patent ductus arteriosus. We report a series of 8 neonates (birth weight: 724 ± 173 g; gestational age: 26 ± 2 weeks) treated with paracetamol for a hemodynamically significant patent ductus arteriosus, because of contraindications to ibuprofen or indomethacin. Successful closure was achieved in 6 out of 8 babies (75%). Median ductal diameter was significantly reduced after treatment (from 1.2 mm, range 1.0-2.5 mm to 0.6 mm, range 0.0-2.5 mm, p = 0.038). No adverse or side effects were observed during treatment. On the basis of these results, paracetamol could be considered a promising and safe therapy for the treatment of patent ductus arteriosus in neonates.

Keywords

Patent ductus arteriosus Paracetamol COX-inhibitors Ibuprofen Indomethacin

Background

A persistently patent ductus arteriosus (PDA) has significant clinical consequences in preterm neonates during the recovery period from respiratory distress syndrome [1]. Ductal patency is regulated by the circulating prostaglandins (PGs) produced by an enzyme system, namely prostaglandin-H2 synthetase (PGHS), which is composed of two active sites: cyclo-oxygenase (COX) and peroxidase [2, 3]. Indomethacin and ibuprofen are COX-inhibitor drugs commonly used for the treatment of hemodynamically significant (hs)-PDA. Despite the about 70% success rate, COX-inhibitors are frequently contraindicated in early life and their use has been associated with serious adverse events, such as gastrointestinal perforation, renal failure and bleeding [411]. Paracetamol, an inhibitor of the peroxidase component of PGHS, is commonly used in pediatric age, and has been recently proposed for the treatment of PDA [1222]. We aimed to evaluate the efficacy of paracetamol in the early treatment of PDA in preterm neonates presenting contraindication to COX-inhibitors.

Case presentation

We report a case series of neonates with hs-PDA treated with paracetamol because of contraindication to ibuprofen or indomethacin, who were observed at the Neonatal Intensive Care Unit of the University of Rome “Sapienza”, from January 2012 to October 2013. During this study period, based on our policy, neonates with gestational age (GA) at birth < 32 weeks were evaluated daily to detect the presence of hs-PDA. Neonates with hs-PDA were treated with paracetamol in the presence of contraindications to ibuprofen or indomethacin (i.e. urine output < 1 ml/kg/h, intraventricular hemorrhage, platelet count < 60,000/mm3, hyperbilirubinemia requiring exchange transfusion, signs of feeding intolerance or gastrointestinal bleeding). The condition of hs-PDA was defined by the presence of at least one of the following criteria: internal ductal diameter ≥ 1.5 mm, left-atrium-to-aortic-root ratio > 1.6, unrestrictive pulsatile transductal flow, reverse or absent diastolic flow in the descending aorta [23]. Paracetamol was given at doses ranging from 7.5 to 15 mg/kg every 4–6 hours, with a maximum daily dose of 60 mg/Kg. We collected, in a specific reporting form, data regarding GA, sex, mode of delivery, birth weight (BW), Apgar score at 5 minutes, weight at enrollment, age at enrollment, contraindication to COX-inhibitor use and echocardiographic characteristics of PDA before and after therapy, obtained from the clinical charts and nursing records. Efficacy was defined by the rate of patients in whom we observed ductal closure (defined by the absence of shunt or diameter < 0.5 mm without any other hemodynamic implications) at echocardiographic examination performed daily during the study period. To monitor safety of paracetamol treatment, we collected data regarding serum concentration of liver enzymes, total and direct bilirubin, creatinine and urea nitrogen. Occurrence of common morbidities of prematurity (i.e. bronchopulmonary dysplasia, intraventricular hemorrhage, necrotizing enterocolitis), fatal events and side effects were also collected. The study was approved by the ethics committee of University of Rome La Sapienza. The χ2 test and Fisher’s exact test were used for categorical variables. The level of significance for all statistical tests was 2-sided, p < 0.05. Statistical analysis was performed with SPSS Version 16.0 for Windows (SPSS Inc., Chicago, IL).

During the study period we observed 8 neonates treated with paracetamol for an hs-PDA. Successful closure was obtained in 6 out of 8 neonates. Median ductal diameter was significantly reduced after treatment (from 1.2 mm, range 1.0-2.5 mm to 0.6 mm, range 0.0-2.5 mm, p = 0.038). Baseline clinical findings, contraindications to COX-inhibitors and echocardiographic characteristics of our study population are reported in Table 1.
Table 1

Main demographic, clinical and echocardiographic findings of preterm neonates before treatment with paracetamol

Characteristics at baseline

 

Demographic and clinical features

 

 N.

8

 Body weight at birth, g

724 ± 173

 Gestational age at birth, weeks

26 ± 2

 Caesarian section, n (%)

6 (75.0)

 Male, n (%)

6 (75.0)

 Apgar at 5 minutes

5 ± 1

 Resuscitation at birth, n (%)

8 (100)

 Body weight at enrollment, g

743.7 ± 167.6

 Age at enrollment, h

66 ± 28

Contraindication to COX-inhibitors

 

 Oliguria, n (%)

4 (50.0)

 Thrombocytopenia, n (%)

2 (25.0)

 Intraventricular hemorrhage, n (%)

1 (12.5)

 Blood in gastric aspirates, n (%)

1 (12.5)

 Hyperbilirubinemia requiring phototherapy, n (%)

4 (50.0)

 Hyperbilirubinemia requiring exchange transfusion, n (%)

0 (0.0)

Echocardiographic findings

 

 Diameter of the ductus ≥ 1.5 mm, n (%)

3 (37.5)

 Left-atrium-to-aortic-root ratio > 1.6, n (%)

6 (75.0)

 Unrestrictive pulsatile transductal flow, n (%)

1 (12.5)

 Reverse flow in the descending aorta, n (%)

2 (25.0)

Notes. Data are expressed as mean ± standard deviation, when not specified.

The two patients in whom paracetamol failed to close the ductus, intravenous ibuprofen (at a dose of 10 mg/kg followed by 5 mg/kg after 24 and 48 hours) was given considering that previous contraindications were no longer present. Surgical ligation was finally needed for both patients after ibuprofen failure. None of our patients experienced re-opening of the ductus after closure. No adverse or side effects were observed during treatment (Table 2). One of the 2 patients who failed treatment with paracetamol developed bronchopulmonary dysplasia.
Table 2

Serum level of liver enzymes and bilirubin before and after treatment with paracetamol

 

At baseline

At end of therapy

p

Safety

   

 Alanine aminotransferase, U/L

56 (8-78)

55 (4-78)

0.878

 Aspartate aminotransferase, U/L

54 (26-80)

31 (8-62)

0.015

 Bilirubinemia, mg/dl

7.6 (3.4-12.8)

5.0 (2.7-7.5)

0.050

Notes. Data are expressed as median (range: upper - lower values).

Conclusions

Our case series demonstrates the efficacy of paracetamol in hs-PDA in preterm neonates with contraindication to COX inhibitors. Nine case series involving a total number of 67 neonates treated with paracetamol for PDA, have been previously reported [1220]. The larger series evaluating efficacy of paracetamol in a similar setting, included a maximum number of 10 patients [13, 16, 20]. Six studies verified the efficacy of paracetamol in very low birth weight neonates [12, 13, 16, 17, 19, 20]; four of them reported a rate of ductal closure of 71-100% [12, 13, 16, 17], while 2 series observed a very low efficacy rate (i.e. 0-20%) [19, 20]. In particular, Alan S. et al. reported the failure of paracetamol in 3 neonates treated with this drug after one or more unsuccessful courses of ibuprofen [19]. In the case series reported by Roofthooft et al., paracetamol was ineffective in 8 out of 10 neonates [20]; however, these patients had a lower GA and BW [20] and started paracetamol treatment later [19, 20] than the patients in our case series. All these data suggest that lower GA and BW associated with previous courses of ibuprofen or later ductal treatment may negatively influence the response to paracetamol [2426]. Accordingly, we observed a failure of paracetamol treatment in 2 subjects with very low GA. On the other hand, the high rate of ductal closure observed in our population could be associated with the earlier start of paracetamol treatment compared with the vast majority of the previous reports.

In five previous studies, paracetamol was administered by enteral route [12, 1416, 18] and in 4 by intravenous route [13, 17, 19, 20]. All of our patients were given paracetamol intravenously because they presented signs of feeding intolerance (i.e., gastric residuals, vomiting, abdominal distension). Even if parenteral route is associated with higher peak and less variability of plasma concentration [27], apparently a similar rate of ductal closure was observed also in reports using oral paracetamol. High doses (60 mg/kg/day) of paracetamol were used in 7 out of 9 previous studies [1215, 1820], while 2 studies reported the administration of lower doses of paracetamol (30–45 mg/kg/day), apparently without any reduction in efficacy [16, 17]. However no study comparing different dosing regimens is available at the moment.

The mechanism of action of paracetamol remains largely uninvestigated. Paracetamol, by inhibiting PG production [3], firstly induces smooth muscle constriction and narrowing of the lumen, similarly to COX-inhibitors. In the subsequent phases of ductal closure, platelet aggregation plays a crucial role in the formation of a thrombus that occludes ductal lumen [28, 29]. A lower anti-platelet activity of paracetamol compared to that of COX-inhibitors may positively influence this phase of the closure process [3]. In any case, future studies should be performed to shed light on the mode of action of paracetamol.

Although interesting, the results of our study suffer from some limitations. Similarly to previous case series, ours is based on a limited number of neonates. Recently, two randomized clinical trials have demonstrated similar efficacy of oral paracetamol compared with oral ibuprofen [21, 22]. Although interesting, results of these trials do not clarify many aspects related to paracetamol use in neonatal age (i.e., optimal dosage, time to start therapy and route of administration). In addition these trials present significant limitations such as inadequate sample power calculation and absence of per intention-to-treat analysis. Pharmacokinetic studies were not performed in our population to avoid adjunctive procedures and blood collections in preterm infants at high risk of iatrogenic anemia [30, 31]. Nevertheless previous studies have demonstrated that the doses used in our study are safe and associated with optimal levels of serum paracetamol concentrations [13].

Our results encourage further well designed studies aimed at verifying the efficacy of paracetamol also as first choice agent in the treatment of PDA.

Consent

Written informed consent was obtained from the parents of the patients for the publication of this report.

Abbreviations

BW: 

Birth weight

COX: 

Cyclo-oxygenase

GA: 

Gestational age

Hs-PDA: 

Hemodynamically significant-patent ductus arteriosus

PDA: 

Patent ductus arteriosus

PGHS: 

Prostaglandin-H2 synthetase

PGs: 

Prostaglandins.

Declarations

Authors’ Affiliations

(1)
Department of Gynecology-Obstetrics and Perinatal Medicine, University “La Sapienza”
(2)
Department of Pediatrics, University “La Sapienza”

References

  1. Hamrick SE, Hansmann G: Patent ductus arteriosus of the preterm infant. Pediatrics. 2010, 125 (5): 1020-1030. 10.1542/peds.2009-3506.View ArticlePubMedGoogle Scholar
  2. Clyman RI: Mechanisms regulating the ductus arteriosus. Biol Neonate. 2006, 89 (4): 330-335. 10.1159/000092870.View ArticlePubMedGoogle Scholar
  3. Graham GG, Davies MJ, Day RO, Mohamudally A, Scott KF: The modern pharmacology of paracetamol: therapeutic actions, mechanism of action, metabolism, toxicity and recent pharmacological findings. Inflammopharmacol. 2013, 21 (3): 201-232. 10.1007/s10787-013-0172-x.View ArticleGoogle Scholar
  4. Van Overmeire B, Smets K, Lecoutere D, Van De Broek H, Weiler J, De Groote K, Langhendries JP: A comparison of ibuprofen and indhomethacin for closure of patent ductus arteriosus. N Engl J Med. 2000, 343 (10): 674-681. 10.1056/NEJM200009073431001.View ArticlePubMedGoogle Scholar
  5. Ohlsson A, Walia R, Shah SS: Ibuprofen for the treatment of patent ductus arteriosus in preterm and/or low birth weight infants. Cochrane database Syst Rev. 2013, 30 (4): CD003481-Google Scholar
  6. Fujii AM, Brown E, Mirochnick M, O’Brien S, Kaufman G: Neonatal necrotizing enterocolitis with intestinal perforation in extremely premature infants receiving early indomethacin treatment for patent ductus arteriosus. J Perinatol. 2002, 22 (7): 535-540. 10.1038/sj.jp.7210795.View ArticlePubMedGoogle Scholar
  7. Shorter NA, Liu JY, Mooney DP, Harmon BJ: Indomethacin-associated bowel perforations: a study of possible risk factors. J Pediatr Surg. 1999, 34 (3): 442-444. 10.1016/S0022-3468(99)90495-5.View ArticlePubMedGoogle Scholar
  8. Bagnoli F, Rossetti A, Messina G, Mori A, Casucci M, Tomasini B: Treatment of patent ductus arteriosus (PDA) using ibuprofen: renal side-effects in VLBW and ELBW newborns. J Matern Fetal Neonatal Med. 2013, 26 (4): 423-429. 10.3109/14767058.2012.733775.View ArticlePubMedGoogle Scholar
  9. Erdeve O, Sarici SU, Sari E, Gok F: Oral-ibuprofen-induced acute renal failure in a preterm infant. Pediatr Nephrol. 2008, 23 (9): 1565-1567. 10.1007/s00467-008-0835-9.View ArticlePubMedGoogle Scholar
  10. Akima S, Kent A, Reynolds GJ, Gallagher M, Falk MC: Indomethacin and renal impairment in neonates. Pediatr Nephrol. 2004, 19 (5): 490-493. 10.1007/s00467-003-1402-z.View ArticlePubMedGoogle Scholar
  11. Kanmaz G, Erdeve O, Canpolat FE, Oğuz SS, Uras N, Altug N, Greijdanus B, Dilmen U: Serum ibuprofen levels of extremely preterm infants treated prophylactically with oral ibuprofen to prevent patent ductus arteriosus. Eur J Clin Pharmacol. 2013, 69 (5): 1075-1081. 10.1007/s00228-012-1438-8.View ArticlePubMedGoogle Scholar
  12. Hammerman C, Bin-Nun A, Markovitch E, Schimmel MS, Kaplan M, Fink D: Ductal closure with paracetamol: a surprising new approach to patent ductus arteriosus treatment. Pediatrics. 2011, 128 (6): e1618-e1621. 10.1542/peds.2011-0359.View ArticlePubMedGoogle Scholar
  13. Oncel MY, Yurttutan S, Degirmencioglu H, Uras N, Altug N, Erdeve O, Dilmen U: Intravenous paracetamol treatment in the management of patent ductus arteriosus in extremely low birth weight infants. Neonatology. 2013, 103: 165-168.View ArticleGoogle Scholar
  14. Yurttutan S, Oncel MY, Arayıcı S, Uras N, Altug N, Erdeve O, Dilmen U: A different first-choice drug in the medical management of patent ductus arteriosus: oral paracetamol. J Matern Fetal Neonatal Med. 2013, 26 (8): 825-827. 10.3109/14767058.2012.755162.View ArticlePubMedGoogle Scholar
  15. Oncel MY, Yurttutan S, Uras N, Altug N, Ozdemir R, Ekmen S, Erdeve O, Dilmen U: An alternative drug (paracetamol) in the management of patent ductus arteriosus in ibuprofen-resistant or contraindicated preterm infants. Arch Dis Child Fetal Neonatal Ed. 2013, 98 (1): F94-10.1136/archdischild-2012-302044.View ArticlePubMedGoogle Scholar
  16. Sinha R, Negi V, Dalal SS: An interesting observation of PDA closure with oral paracetamol in preterm neonates. J Clin Neonatol. 2013, 2 (1): 30-32. 10.4103/2249-4847.109245.PubMed CentralView ArticlePubMedGoogle Scholar
  17. Tekgunduz KS, Ceviz N, Demirelli Y, Olgun H, Caner I, Sahin IO, Yolcu C: Intravenous paracetamol for patent ductus arteriosus in premature infants - a lower dose is also effective. Neonatology. 2013, 104 (1): 6-7. 10.1159/000348568.View ArticlePubMedGoogle Scholar
  18. Ozdemir OM, Doğan M, Küçüktaşçı K, Ergin H, Sahin O: Paracetamol therapy for patent ductus arteriosus in premature infants: a chance before surgical ligation. Pediatr Cardiol. 2013, [Epub ahead of print]Google Scholar
  19. Alan S, Kahvecioglu D, Erdeve O, Atasay B, Arsan S: Is paracetamol a useful treatment for ibuprofen-resistant patent ductus arteriosus?. Neonatology. 2013, 104 (3): 168-169. 10.1159/000352068.View ArticlePubMedGoogle Scholar
  20. Roofthooft DW, van Beynum IM, Helbing WA, Reiss IK, Simons SH: Paracetamol for ductus arteriosus closure: not always a success story. Neonatology. 2013, 104 (3): 170-10.1159/000353451.View ArticlePubMedGoogle Scholar
  21. Dang D, Wang D, Zhang C, Zhou W, Zhou Q, Wu H: Comparison of oral paracetamol versus ibuprofen in premature infants with patent ductus arteriosus: a randomized controlled trial. PLoS One. 2013, 8 (11): e77888-10.1371/journal.pone.0077888.PubMed CentralView ArticlePubMedGoogle Scholar
  22. Oncel MY, Yurttutan S, Erdeve O, Uras N, Altug N, Oguz SS, Canpolat FE, Dilmen U: Oral paracetamol versus oral ibuprofen in the management of patent ductus arteriosus in preterm infants. A randomized controlled trial. J Pediatr. 2013, 01394-2-doi: 10.1016/j.jpeds.2013.11.008. [Epub ahead of print], 13Google Scholar
  23. McNamara PJ, Sehgal A: Towards rational management of the patent ductus arteriosus: the need for disease staging. Arch Dis Child Fetal Neonatal Ed. 2007, 92 (6): F424-F427. 10.1136/adc.2007.118117.PubMed CentralView ArticlePubMedGoogle Scholar
  24. Koch J, Hensley G, Roy L, Brown S, Ramaciotti C, Rosenfeld CR: Prevalence of spontaneous closure of the ductus arteriosus in neonates at a birth weight of 1000 grams or less. Pediatrics. 2006, 117 (4): 1113-1121. 10.1542/peds.2005-1528.View ArticlePubMedGoogle Scholar
  25. Dani C, Bertini G, Corsini I, Elia S, Vangi V, Pratesi S, Rubaltelli FF: The fate of ductus arteriosus in infants at 23-27 weeks of gestation: from spontaneous closure to ibuprofen resistance. Acta Paediatr. 2008, 97 (9): 1176-1180. 10.1111/j.1651-2227.2008.00871.x.View ArticlePubMedGoogle Scholar
  26. Chorne N, Jegatheesan P, Lin E, Shi R, Clyman RI: Risk factors for persistent ductus arteriosus patency during indomethacin treatment. J Pediatr. 2007, 151 (6): 629-634. 10.1016/j.jpeds.2007.05.007.View ArticlePubMedGoogle Scholar
  27. Van der Westhuizen J, Kuo PY, Reed PW, Holder K: Randomised controlled trial comparing oral and intravenous paracetamol (acetaminophen) plasma levels when given as preoperative analgesia. Anaesth Intensive Care. 2011, 39 (2): 242-246.PubMedGoogle Scholar
  28. Echtler K, Stark K, Lorenz M, Kerstan S, Walch A, Jennen L, Rudelius M, Seidl S, Kremmer E, Emambokus NR, von Bruehl ML, Frampton J, Isermann B, Genzel-Boroviczény O, Schreiber C, Mehilli J, Kastrati A, Schwaiger M, Shivdasani RA, Massberg S: Platelets contribute to postnatal occlusion of the ductus arteriosus. Nat Med. 2010, 16 (1): 75-82. 10.1038/nm.2060.View ArticlePubMedGoogle Scholar
  29. Clyman R, Chemtob S: Vessel remodeling in the newborn: platelets fill the gap. Nat Med. 2010, 16 (1): 33-35. 10.1038/nm0110-33.View ArticlePubMedGoogle Scholar
  30. Strauss RG: Anaemia of prematurity: pathophysiology and treatment. Blood Rev. 2010, 24 (6): 221-225. 10.1016/j.blre.2010.08.001.PubMed CentralView ArticlePubMedGoogle Scholar
  31. Vandenberg KA: Individualized developmental care for high risk newborns in the NICU: a practice guideline. Early Hum Dev. 2007, 83 (7): 433-442. 10.1016/j.earlhumdev.2007.03.008.View ArticlePubMedGoogle Scholar

Copyright

© Terrin et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.